Company Overview of Hawaii Biotech, Inc.
Hawaii Biotech, Inc., a biotechnology company, researches and develops prophylactic vaccines for infectious diseases. The company provides a recombinant proteins production platform that has application to the manufacture vaccines, diagnostic kits, and research tools. Its technology platform develops vaccines for various diseases, including West Nile, dengue, tick borne encephalitis, influenza, hepatitis C, malaria, Japanese encephalitis, Ebola, Eastern equine encephalitis, and others. The company also develops recombinant subunit protein vaccines focusing on the quality of recombinant protein produced and its impact on immunogenicity; and GPI-0100, a saponin adjuvant useful in helping to el...
99-193 Aiea Heights Drive
Aiea, HI 96701
Founded in 1982
Key Executives for Hawaii Biotech, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Chief Operations Officer
General Counsel, Vice President of Business Development, Secretary and Director
Director of Molecular Biology and Cell Culture
Compensation as of Fiscal Year 2016.
Hawaii Biotech, Inc. Key Developments
Hawaii Biotech, Inc. Receives Contract to Develop Dengue Vaccine
Dec 4 15
Hawaii Biotech, Inc. announced that the US Army SBIR Program awarded the company a Small Business Innovation Research Phase I contract to develop an effective dengue vaccine to protect military personnel against this potentially mission-aborting disease. Current leading dengue vaccine candidates in clinical trails offer only partial protection and long immunization periods. International travelers and military personnel being deployed to tropical or subtropical regions require more immediate and more complete immunity. Specifically, HBI will develop and test novel adjuvants to enhance the immunogenicity of an inactivated dengue vaccine candidate. This effort takes the initial steps toward developing the world's first vaccine capable of rapidly generating complete, lasting protection from dengue fever. In Phase I, HBI will select suitable adjuvant formulations and then demonstrate protective efficacy in a mouse model with a single dengue serotype. Upon successful completion of Phase I, HBI will be eligible to apply for Phase II funding that will continue development of the inactivated dengue vaccine candidate. This will include expanding the work to all four dengue serotypes to establish feasibility of the required tetravalent vaccine for dengue and additional preclinical efficacy studies. A successful Phase II outcome will provide the basis for advancement of the dengue vaccine into clinical trials needed for regulatory approval and commercialization. This contract was funded by the Army SBIR Program. The work is managed by the US Army Medical Research and Materiel Command under Contract No. W81XWH-15-C-0120 and will be managed and done in collaboration with the Viral and Rickettsial Diseases Department at the Naval Medical Research Center.
Soligenix Announces Collaboration with the University of Hawai'i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine
May 28 15
Soligenix, Inc. announced a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa) and Hawaii Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates. Under the terms of the feasibility agreement, Soligenix will evaluate its proprietary vaccine thermostabilization technology, ThermoVax™, licensed from the University of Colorado, to stabilize components of the vaccine. Ultimately, the objective is to produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage. ThermoVax™ has been previously demonstrated to enhance thermostability of both ricin (RiVax™) and anthrax (VeloThrax™) subunit vaccines. The initial work on the potential Ebola vaccine will focus on a single protein subunit antigen. The most advanced Ebola vaccines involve the use of vesicular stomatitis virus (VSV) and adenovirus vectors – live, viral vectors which complicate the manufacturing, stability and storage requirements. Dr. Lehrer's vaccine is based on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties. Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of ThermoVax™ may allow for a product that can avoid the need for cold-chain distribution and storage, yielding a vaccine ideal for use in both the developed and developing world.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|